Title

Considering metformin as a second-line treatment for children and adolescents with prediabetes.

Document Type

Article

Publication Date

6-27-2022

Identifier

DOI: 10.1515/jpem-2021-0200

Abstract

Overweight and obesity affect approximately 1/3 of children in the United States and are risk factors for prediabetes and type 2 diabetes. Progression from prediabetes to diabetes carries substantial long-term health burdens, culminating in decreased life-expectancy. Earlier development of type 2 diabetes is associated with poorer prognoses, and children lose glycemic control more rapidly than adults. Metformin is approved by the USFDA for the treatment of type 2 diabetes in children, has limited toxicity, and may help prevent the development of type 2 diabetes. The more rapid disease progression in children and the safety of metformin suggests that initiation of metformin treatment to children with prediabetes who have not effectively responded to lifestyle changes may help prevent short- and long-term health damage resulting from prediabetic and diabetic dysglycemia.

Journal Title

Journal of pediatric endocrinology & metabolism : JPEM

Volume

35

Issue

6

First Page

727

Last Page

732

MeSH Keywords

Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Metformin; Prediabetic State; United States

Keywords

metformin; pediatrics; prediabetes

Library Record

Share

COinS